文献速递泌尿男性生殖肿瘤

KEYNOTE-427最终结果:帕博利珠单抗一线治疗晚期肾细胞癌的疗效与预测生物标志物

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.
PubMed 文献 · Ann Oncol · 2026-09-29

KEYNOTE-427是一项单臂II期研究,评估帕博利珠单抗单药一线治疗晚期透明细胞肾细胞癌(ccRCC,队列A)和非透明细胞肾细胞癌(nccRCC,队列B)的疗效与安全性。最终分析显示,队列A和B的客观缓解率(ORR)分别为36.4%和26.7%,中位随访分别为61.1个月和56.7个月。T细胞炎症基因表达谱(TcellinfGEP)和PD-L1联合阳性评分(CPS)与ORR正相关,基线可检测循环肿瘤DNA(ctDNA)者总生存(OS)较短。

要点

  • 帕博利珠单抗一线治疗ccRCC和nccRCC的ORR分别为36.4%和26.7%。
  • TcellinfGEP和PD-L1 CPS与ORR正相关,CPS还与PFS和OS相关。
  • 基线ctDNA阳性者中位OS为30.5个月,短于阴性者的53.7个月。

核心结论

  • 帕博利珠单抗在ccRCC和nccRCC中均显示高活性。
  • 对RCC肿瘤分子组分和ctDNA的综合分析可能推动生物标志物驱动的精准治疗。

研究设计与样本

  • 单臂、II期KEYNOTE-427研究,纳入既往未接受系统治疗的局部晚期、复发或转移性ccRCC(队列A)或nccRCC(队列B)患者。
  • 主要终点为盲态独立中心审查按RECIST v1.1评估的客观缓解率(ORR)。
  • 预设生物标志物分析评估TcellinfGEP、PD-L1 CPS、RCC驱动基因突变和ctDNA(队列A)与临床结局的关联。

主要发现

  • 队列A中位随访61.1个月(范围54.7-65.5),ORR为36.4%。
  • 队列B中位随访56.7个月(范围47.9-64.0),ORR为26.7%。
  • 连续TcellinfGEP与队列A的ORR正相关(P=0.0208),与队列B的ORR正相关(P=0.0021)。
  • 连续PD-L1 CPS与队列A的ORR(P=0.0195)和无进展生存期(PFS;P=0.0307)正相关。
  • 连续PD-L1 CPS与队列B的ORR(P<0.0001)、PFS(P=0.0002)和总生存期(OS;P=0.0014)正相关。

关键数值与推荐

  • 队列A中,基线可检测ctDNA者中位OS为30.5个月(95%置信区间18.1-56.4),ctDNA阴性者为53.7个月(28.7-未达到)。
  • RCC驱动基因突变在两个队列中均未显示与ORR的一致关联模式。

临床怎么用

  • 帕博利珠单抗单药可作为晚期ccRCC和nccRCC一线治疗选择之一。
  • TcellinfGEP和PD-L1 CPS可能有助于预测帕博利珠单抗治疗反应。
  • 基线ctDNA检测可能有助于识别OS较短的高危患者。

局限性

  • 单臂II期研究设计,无对照组,结论需在随机研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous results from the single-arm, phase II KEYNOTE-427 study showed antitumor activity with first-line pembrolizumab monotherapy in advanced clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC). We report results of the final efficacy and safety analyses and exploratory predictive biomarker analysis of KEYNOTE-427. PATIENTS AND METHODS: Eligible participants had histologically confirmed locally advanced, recurrent, or metastatic ccRCC (cohort A) or nccRCC (cohort B) with or without sarcomatoid features, measurable disease per RECIST v1.1, and no prior systemic therapy for advanced RCC. The primary end point was objective response rate (ORR) per RECIST v1.1 by blinded independent central review. Prespecified biomarker objectives were to evaluate the association of clinical outcomes with a T-cell-inflamed gene expression profile (TcellinfGEP), programmed cell death ligand 1 combined positive score (PD-L1 CPS), RCC driver gene mutations, and circulating tumor DNA (ctDNA; cohort A). RESULTS: After a median (range) follow-up of 61.1 months (54.7-65.5) in cohort A and 56.7 months (47.9-64.0) in cohort B, ORRs were 36.4% and 26.7%, respectively. Continuous TcellinfGEP was positively associated with ORR in cohort A (P = 0.0208) and cohort B (P = 0.0021). Continuous PD-L1 CPS was positively associated with ORR (P = 0.0195) and progression-free survival (PFS; P = 0.0307) in cohort A and ORR (P < 0.0001), PFS (P = 0.0002), and overall survival (OS; P = 0.0014) in cohort B. RCC driver gene mutations showed no consistent patterns with ORR in either cohort. In cohort A, participants with detectable ctDNA at baseline had a shorter OS than participants with a ctDNA-negative status [median: 30.5 months (95% confidence interval 18.1-56.4) versus 53.7 months (28.7-not reached)]. CONCLUSIONS: These results show that pembrolizumab is a highly active agent in ccRCC and nccRCC. Insights from the comprehensive analysis of RCC tumor molecular components and ctDNA may facilitate progress toward effective, biomarker-driven precision treatment in advanced RCC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. McDermott DF, Signoretti S, Lee JL, et al. Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study. Ann Oncol. 2026. PMID: 42810586. doi:10.1016/j.annonc.2026.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。